Market Cap
$6.3B
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
$14.24 ▲ +0.07%
Prev close $14.23Market cap$6.3B
ConsensusStrong Buy
12-mo target$12.80 (-10.0%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (7/10)36 New Institutional Positions14 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on IOVA right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (80%)
Inst. Holders
50 funds
Inst. Value
$904.3M
Inst. Activity
36 buys / 14 sells
Social Sentiment
70° Bullish
SEC Reports
8
Press Releases
4
Price chart 30d +65.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Leader in Global Drug Development of T Cell Therapies
Sep 8, 2026 Insider
Vogt Frederick G acquired via exercise 15,626 shares
Interim CEO & General Counsel
Sep 8, 2026 Insider
BILINSKY IGOR surrendered for taxes 3,976 shares
Chief Operating Officer @ $8.70 ($34.6K)
Sep 8, 2026 Insider
Aug 21, 2026 Press Puri Raj K. surrendered for taxes 4,478 shares
Chief Regulatory Officer @ $8.70 ($39.0K)
Iovance Biotherapeutics granted inducement stock options covering 240,135 shares to 20 new non-executive employees at an
Impact 2/10
Iovance Biotherapeutics filed an 8-K with an updated corporate presentation used at healthcare conferences. The presenta
8-K — Impact 3/10
Iovance reported record Q2 2026 revenue of ~$99.3M, a 66% YoY increase, driven by U.S. Amtagvi revenue of ~$91M. Gross m
8-K — Impact 7/10
Iovance Biotherapeutics lost a summary judgment ruling in its insurance coverage dispute with Federal Insurance Company.
COURT-RULING — Impact 5/10
Analyst ratings buy % +19.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
80% rate it Buy or better · 15 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Sep 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Sep 17, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Aug 25, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Aug 20, 2026 | UBS | MAINTAIN | Neutral | 55% |
| Aug 18, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Aug 7, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Aug 7, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| May 8, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
| Apr 10, 2026 | Chardan Capital | MAINTAIN | Buy | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 9 | 3 | 0 | 0 | 80% | |
| Aug 1, 2026 | 3 | 9 | 3 | 0 | 0 | 80% | |
| Jul 1, 2026 | 3 | 10 | 3 | 0 | 0 | 81% | |
| Jun 1, 2026 | 3 | 10 | 3 | 0 | 0 | 81% | |
| May 1, 2026 | 3 | 10 | 4 | 0 | 0 | 76% | |
| Apr 1, 2026 | 3 | 10 | 4 | 0 | 0 | 76% | |
| Mar 1, 2026 | 3 | 10 | 4 | 0 | 0 | 76% | |
| Feb 1, 2026 | 3 | 9 | 5 | 1 | 0 | 67% |
Price targets
Where 10 covering analysts think IOVA trades over the next 12 months.
$12.80 -10.0% upside Sell
Current$14.22 Low$6.00 Median$13.50 High$20.00 10 analysts
$6.00$20.00
Analyst rating Buy· 1.6/5 as of Oct 2, 2026
Social media sentiment mood +20.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
70°
Bullish
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 2 bullish, 1 bearish, 0 mixed, 5 neutral · avg impact 4.4/10.Plus 4 press releases.
NEUTRAL8-K3/10
Iovance Biotherapeutics filed an 8-K with an updated corporate presentation used at healthcare confe
Aug 6, 2026
BULLISH8-K7/10
Iovance reported record Q2 2026 revenue of ~$99.3M, a 66% YoY increase, driven by U.S. Amtagvi reven
Aug 6, 2026
BEARISHCOURT-RULING5/10
Iovance Biotherapeutics lost a summary judgment ruling in its insurance coverage dispute with Federa
Jul 17, 2026
NEUTRAL8-K2/10
Iovance Biotherapeutics filed an 8-K to update its corporate presentation, which is a routine admini
Jul 2, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Leader in Global Drug Development of T Cell Therapies
Sep 25, 2026
Clinical Trial
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Phase Phase 2 — TERMINATED
Sep 18, 2026
other
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology comp
Sep 10, 2026
short_volume
Short Volume: IOVA — 57.2% short (3.5M / 6.2M)
Short: 3,546,743 | Exempt: 2,400 | TRF Vol: 6,200,208 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Sep 4, 2026
other
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, de
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.09 | $-0.10–$-0.07 | 65.4% | +10.0% | 6↑ 0↓ | $0.1B | 8 |
| Next Q | $-0.08 | $-0.12–$-0.04 | 53.3% | +21.0% | 5↑ 1↓ | $0.1B | 8 |
| Current FY | $-0.46 | $-0.50–$-0.41 | 58.1% | +7.8% | 6↑ 0↓ | $0.4B | 8 |
| Next FY | $-0.24 | $-0.42–$-0.10 | 48.2% | +17.5% | 5↑ 2↓ | $0.6B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.086 | — |
| 7d ago | $-0.096 | +0.009 |
| 30d ago | $-0.096 | +0.010 |
| 60d ago | $-0.126 | +0.039 |
| 90d ago | $-0.125 | +0.038 |
Institutional ownership
Which big funds own IOVA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $904.3M total value (217,420,988 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, TWO. Net buying activity: 36 institutions added/increased vs 14 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 36,957,681 | $153.7M | 17.0% | — |
| STATE STREET CORP | 24,478,268 | $101.8M | 11.3% | ADD +40.3% |
| TWO SIGMA INVESTMENTS, LP | 19,010,697 | $79.1M | 8.7% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 18,204,248 | $75.7M | 8.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 14,388,999 | $59.9M | 6.6% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 10,324,826 | $43.0M | 4.8% | — |
| MILLENNIUM MANAGEMENT LLC | 8,525,919 | $35.5M | 3.9% | — |
| DIMENSIONAL FUND ADVISORS LP | 6,460,449 | $26.9M | 3.0% | DOUBLED +144.2% |
| GOLDMAN SACHS GROUP INC | 5,096,334 | $21.2M | 2.3% | TRIM -41.8% |
| Nuveen, LLC | 4,997,112 | $20.8M | 2.3% | ADD +36.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 17,448,108 | 24,478,268 | +40.3% | $101.8M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 2,645,702 | 6,460,449 | +144.2% | $26.9M |
| GOLDMAN SACHS GROUP INC | TRIM | 8,760,060 | 5,096,334 | -41.8% | $21.2M |
| Nuveen, LLC | ADD | 3,664,278 | 4,997,112 | +36.4% | $20.8M |
| BANK OF AMERICA CORP /DE/ | TRIM | 8,490,119 | 4,993,584 | -41.2% | $20.8M |
| JUPITER ASSET MANAGEMENT LTD | NEW | — | 4,535,080 | — | $18.9M |
| NORTHERN TRUST CORP | ADD | 2,875,526 | 4,154,200 | +44.5% | $17.3M |
| WELLS FARGO & COMPANY/MN | ADD | 2,071,524 | 3,246,537 | +56.7% | $13.5M |
| D. E. Shaw & Co., Inc. | TRIM | 8,016,353 | 2,143,134 | -73.3% | $8.9M |
| FMR LLC | DOUBLED | 49,301 | 1,355,378 | +2649.2% | $5.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Vogt Frederick G | Interim CEO & General Counsel | EXERCISE | 15,626 | — | — |
| Sep 8, 2026 | BILINSKY IGOR | Chief Operating Officer | TAX W/H | 3,976 | $8.70 | $34.6K |
| Sep 8, 2026 | Puri Raj K. | Chief Regulatory Officer | TAX W/H | 4,478 | $8.70 | $39.0K |
| Sep 8, 2026 | Puri Raj K. | Chief Regulatory Officer | EXERCISE | 9,766 | — | — |
| Sep 8, 2026 | BILINSKY IGOR | Chief Operating Officer | EXERCISE | 7,813 | — | — |
| Sep 8, 2026 | Vogt Frederick G | Interim CEO & General Counsel | TAX W/H | 6,638 | $8.70 | $57.8K |
| Sep 1, 2026 | Puri Raj K. | Chief Regulatory Officer | EXERCISE | 5,470 | — | — |
| Sep 1, 2026 | Vogt Frederick G | Interim CEO & General Counsel | TAX W/H | 17,702 | $8.28 | $146.6K |
| Sep 1, 2026 | BILINSKY IGOR | Chief Operating Officer | EXERCISE | 8,789 | — | — |
| Sep 1, 2026 | Vogt Frederick G | Interim CEO & General Counsel | EXERCISE | 41,669 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for IOVA.
Shares short
87,127,871
Settlement Sep 15, 2026
Change vs prior
-1.1%
Semi-monthly cycle
Days to cover
7.4
At avg daily volume
Of shares outstanding
≈19.2%
Estimate — not % of float
All IOVA filing & press-release reports (12)
- PRESS-RELEASE reportAug 21, 2026
- 8-K reportAug 6, 2026
- 8-K reportAug 6, 2026
- COURT-RULING reportJul 17, 2026
- 8-K reportJul 2, 2026
- PRESS-RELEASE reportJun 19, 2026
- S-3ASR reportJun 19, 2026
- 8-K reportJun 10, 2026
- PRESS-RELEASE reportMay 22, 2026
- DEFA14A reportApr 28, 2026
- PRESS-RELEASE reportApr 27, 2026
- PRESS-RELEASE reportApr 17, 2026